SG10202111098RA - A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy - Google Patents
A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapyInfo
- Publication number
- SG10202111098RA SG10202111098RA SG10202111098RA SG10202111098RA SG10202111098RA SG 10202111098R A SG10202111098R A SG 10202111098RA SG 10202111098R A SG10202111098R A SG 10202111098RA SG 10202111098R A SG10202111098R A SG 10202111098RA SG 10202111098R A SG10202111098R A SG 10202111098RA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer therapy
- whole cell
- checkpoint inhibitor
- cell mycobacterium
- mycobacterium
- Prior art date
Links
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 title 1
- 241000186359 Mycobacterium Species 0.000 title 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 title 1
- 238000011275 oncology therapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1322725.1A GB201322725D0 (en) | 2013-12-20 | 2013-12-20 | Cancer therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202111098RA true SG10202111098RA (en) | 2021-11-29 |
Family
ID=50071260
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202111098RA SG10202111098RA (en) | 2013-12-20 | 2014-12-16 | A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy |
| SG11201604602TA SG11201604602TA (en) | 2013-12-20 | 2014-12-16 | A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201604602TA SG11201604602TA (en) | 2013-12-20 | 2014-12-16 | A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy |
Country Status (18)
| Country | Link |
|---|---|
| US (7) | US10610577B2 (en) |
| EP (1) | EP3082956B1 (en) |
| JP (2) | JP6858558B2 (en) |
| KR (1) | KR101820393B1 (en) |
| CN (2) | CN111671908A (en) |
| AU (2) | AU2014369510B2 (en) |
| BR (1) | BR112016013887B1 (en) |
| CA (1) | CA2932659C (en) |
| ES (1) | ES2913460T3 (en) |
| GB (1) | GB201322725D0 (en) |
| IL (1) | IL246083B2 (en) |
| MX (1) | MX2016007709A (en) |
| NZ (1) | NZ721009A (en) |
| PL (1) | PL3082956T3 (en) |
| PT (1) | PT3082956T (en) |
| RU (1) | RU2719934C2 (en) |
| SG (2) | SG10202111098RA (en) |
| WO (1) | WO2015092382A1 (en) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4169951A1 (en) | 2008-12-09 | 2023-04-26 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| GB201120779D0 (en) | 2011-12-02 | 2012-01-11 | Immodulon Therapeutics Ltd | Cancer therapy |
| GB201322725D0 (en) * | 2013-12-20 | 2014-02-05 | Immodulon Therapeutics Ltd | Cancer therapy |
| JO3663B1 (en) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | Anti-lag3 antibodies and antigen-binding fragments |
| AU2016281765B2 (en) * | 2015-06-24 | 2022-06-16 | Immodulon Therapeutics Limited | A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy |
| CA3000996A1 (en) * | 2015-10-05 | 2017-04-13 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors and immuno-oncology agents |
| EP3377526A1 (en) * | 2015-11-18 | 2018-09-26 | Merck Sharp & Dohme Corp. | PD1/CTLA4 Binders |
| EP3399989B1 (en) | 2015-12-16 | 2023-08-09 | Merck Sharp & Dohme LLC | Anti-lag3 antibodies and antigen-binding fragments |
| SG11201805556QA (en) * | 2016-01-08 | 2018-07-30 | Momotaro Gene Inc | A combination therapy using REIC/Dkk-3 gene and a checkpoint inhibitor |
| GB201601248D0 (en) * | 2016-01-22 | 2016-03-09 | Immodulon Therapeutics Ltd | Cancer therapy |
| EP3195878A1 (en) * | 2016-01-22 | 2017-07-26 | Werner Lubitz | Bacterial ghosts for the treatment of cancer |
| BR112018074463A2 (en) | 2016-05-27 | 2019-03-06 | Agenus Inc. | anti-tim-3 antibodies and methods of use. |
| KR20190019121A (en) * | 2016-06-17 | 2019-02-26 | 오사카 유니버시티 | Intratumoral intravenous growth promoter |
| CN110475560B (en) * | 2016-12-15 | 2023-06-20 | 普罗基Pg500系列私人有限公司 | Composition and use thereof |
| US11077179B2 (en) | 2017-08-10 | 2021-08-03 | Epicgenetics, Inc. | Method for treating fibromyalgia and chronic fatigue syndrome |
| US11331350B2 (en) | 2017-11-06 | 2022-05-17 | Seoul National University R&Db Foundation | Use of Mycobacterium paragordonae for cancer immunotherapy |
| CA3104218A1 (en) * | 2018-06-25 | 2020-01-02 | Immodulon Therapeutics Limited | Cancer therapy |
| GB201820554D0 (en) * | 2018-12-17 | 2019-01-30 | Univ Oxford Innovation Ltd | BTLA antibodies |
| GB201919428D0 (en) * | 2019-12-30 | 2020-02-12 | Immodulon Therapeutics Ltd | Immunotherapeutic treatment of cancer |
| CN113358872B (en) * | 2021-06-03 | 2022-10-21 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | Marker group and system for evaluating curative effect of tumor immunotherapy |
| US20240024449A1 (en) * | 2022-07-20 | 2024-01-25 | Immunology Diagnostics, LLC | Methods and compositions for improving immune system function |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5207223A (en) | 1990-10-19 | 1993-05-04 | Accuray, Inc. | Apparatus for and method of performing stereotaxic surgery |
| ATE154759T1 (en) | 1990-11-08 | 1997-07-15 | Univ London | MYCOBACTERIUM AS AN ADJUVANT FOR ANTIGENS |
| US5458125A (en) | 1994-01-28 | 1995-10-17 | Board Of Directors Of The Leland Standford Jr. University | Treatment planning method and apparatus for radiosurgery and radiation therapy |
| US20020022032A1 (en) | 1999-04-23 | 2002-02-21 | Curry Patrick Mark | Immuno-adjuvant PDT treatment of metastatic tumors |
| EP1173203A2 (en) | 1999-04-23 | 2002-01-23 | QLT Inc. | Immuno-adjuvant pdt treatment of metastatic tumors |
| AU2002353366A1 (en) | 2001-12-10 | 2003-06-23 | Bakulesh Mafatlal Khamar | The process of manufacturing a pharmaceutical composition useful for management of cancer |
| JP4409430B2 (en) | 2002-07-03 | 2010-02-03 | 小野薬品工業株式会社 | Immunostimulatory composition |
| CN1859851A (en) * | 2002-07-12 | 2006-11-08 | 约翰斯霍普金斯大学 | Mesothelin vaccines and model systems |
| JP2006521090A (en) * | 2002-07-12 | 2006-09-21 | ザ ジョンズ ホプキンス ユニバーシティー | Mesothelin vaccine and model system |
| CA2626547A1 (en) | 2005-10-21 | 2007-05-03 | Medical College Of Georgia Research Institute, Inc. | The induction of indoleamine 2,3-dioxygenase in dendritic cells by tlr ligands and uses thereof |
| US20080318252A1 (en) | 2007-04-23 | 2008-12-25 | Scott Kachlany | Rapid assay to test anti-cancer drugs under physiological conditions |
| GB0526033D0 (en) * | 2005-12-21 | 2006-02-01 | Bioeos Ltd | Method |
| EP2010216A4 (en) | 2006-03-24 | 2010-06-09 | Donald L Morton | Mycobacterial immunotherapy for cancer treatment |
| WO2008110491A2 (en) | 2007-03-09 | 2008-09-18 | University Of Basel | Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat |
| RU2350338C2 (en) * | 2007-05-14 | 2009-03-27 | ФГУ Ростовский научно-исследовательский онкологический институт Росздрава | Method of treatment of superficial cancer of bladder |
| CA2691357C (en) * | 2007-06-18 | 2014-09-23 | N.V. Organon | Antibodies to human programmed death receptor pd-1 |
| RS53782B1 (en) | 2008-10-01 | 2015-06-30 | Immatics Biotechnologies Gmbh | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers |
| US8367075B2 (en) * | 2010-07-02 | 2013-02-05 | Indian Institute Of Science | Synergistic combination and method thereof |
| US9114158B2 (en) | 2011-03-09 | 2015-08-25 | The Johns Hopkins University | Compounds and methods of use in ablative radiotherapy |
| AU2012273182A1 (en) * | 2011-06-21 | 2014-01-16 | The Johns Hopkins University | Focused radiation for augmenting immune-based therapies against neoplasms |
| GB201120779D0 (en) | 2011-12-02 | 2012-01-11 | Immodulon Therapeutics Ltd | Cancer therapy |
| EP2620159A1 (en) | 2012-01-24 | 2013-07-31 | Institut Pasteur | Improved cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria |
| IN2014KN00848A (en) | 2012-02-01 | 2015-10-02 | Compugen Ltd | |
| US8617520B2 (en) * | 2012-02-15 | 2013-12-31 | Immodulon Therapeutics Limited | Cancer therapy |
| AR090263A1 (en) * | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME |
| CA2873402C (en) * | 2012-05-15 | 2023-10-24 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| US9810692B2 (en) * | 2012-10-26 | 2017-11-07 | Institut Gustave Roussy | Methods for predicting the sensitivity of a subject to immunotherapy |
| WO2014181221A2 (en) | 2013-05-08 | 2014-11-13 | Ashwin Bharadwaj | Heat sink |
| GB201308325D0 (en) * | 2013-05-09 | 2013-06-19 | Immodulon Therapeutics Ltd | Cancer Therapy |
| GB201322725D0 (en) | 2013-12-20 | 2014-02-05 | Immodulon Therapeutics Ltd | Cancer therapy |
| CA2935375C (en) | 2014-01-06 | 2023-08-08 | The Trustees Of The University Of Pennsylvania | Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy |
| EP3936145A1 (en) | 2014-07-31 | 2022-01-12 | The University Of Western Australia | A method for the identification of immunotherapy-drug combinations using a network approach |
| US10975112B2 (en) | 2015-06-16 | 2021-04-13 | Hangzhou Dac Biotech Co., Ltd. | Linkers for conjugation of cell-binding molecules |
| AU2016281765B2 (en) | 2015-06-24 | 2022-06-16 | Immodulon Therapeutics Limited | A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy |
| US9861621B2 (en) | 2015-06-29 | 2018-01-09 | Biomed Valley Discoveries, Inc. | LPT-723 and immune checkpoint inhibitor combinations and methods of treatment |
| CA3104218A1 (en) | 2018-06-25 | 2020-01-02 | Immodulon Therapeutics Limited | Cancer therapy |
-
2013
- 2013-12-20 GB GBGB1322725.1A patent/GB201322725D0/en not_active Ceased
-
2014
- 2014-12-16 PT PT148275183T patent/PT3082956T/en unknown
- 2014-12-16 NZ NZ721009A patent/NZ721009A/en unknown
- 2014-12-16 EP EP14827518.3A patent/EP3082956B1/en active Active
- 2014-12-16 WO PCT/GB2014/053717 patent/WO2015092382A1/en active Application Filing
- 2014-12-16 SG SG10202111098RA patent/SG10202111098RA/en unknown
- 2014-12-16 PL PL14827518T patent/PL3082956T3/en unknown
- 2014-12-16 BR BR112016013887-2A patent/BR112016013887B1/en active IP Right Grant
- 2014-12-16 ES ES14827518T patent/ES2913460T3/en active Active
- 2014-12-16 IL IL246083A patent/IL246083B2/en unknown
- 2014-12-16 KR KR1020167015996A patent/KR101820393B1/en active IP Right Grant
- 2014-12-16 RU RU2016123370A patent/RU2719934C2/en active
- 2014-12-16 MX MX2016007709A patent/MX2016007709A/en unknown
- 2014-12-16 CN CN202010559639.9A patent/CN111671908A/en active Pending
- 2014-12-16 JP JP2016541474A patent/JP6858558B2/en active Active
- 2014-12-16 CA CA2932659A patent/CA2932659C/en active Active
- 2014-12-16 US US15/104,890 patent/US10610577B2/en active Active
- 2014-12-16 SG SG11201604602TA patent/SG11201604602TA/en unknown
- 2014-12-16 AU AU2014369510A patent/AU2014369510B2/en active Active
- 2014-12-16 CN CN201480067986.2A patent/CN105979964B/en active Active
-
2018
- 2018-08-24 US US16/112,430 patent/US10610578B2/en active Active
-
2019
- 2019-07-25 JP JP2019137010A patent/JP2019196394A/en active Pending
-
2020
- 2020-03-10 AU AU2020201754A patent/AU2020201754B2/en active Active
- 2020-03-16 US US16/820,058 patent/US10994002B2/en active Active
- 2020-03-16 US US16/819,927 patent/US10925952B2/en active Active
- 2020-03-16 US US16/820,132 patent/US11000584B2/en active Active
-
2021
- 2021-03-31 US US17/301,319 patent/US20210213127A1/en not_active Abandoned
- 2021-03-31 US US17/301,331 patent/US12042532B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL246083A0 (en) | A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy | |
| IL256467A (en) | A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy | |
| HK1257187B (en) | A DEVICE COMPRISING NON-NATIVE PANCREATIC ß CELLS AND USE IN TREATING DISEASES SUCH AS DIABETES | |
| IL272921A (en) | Combination therapy comprising a b-raf inhibitor and a second inhibitor | |
| IL259479B (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| EP2953191A4 (en) | Anion conducting material and battery | |
| SG11201505858VA (en) | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease | |
| HK1209799A1 (en) | A non-invasion cancer detection method and a kit for performing the same | |
| PL3065759T3 (en) | Immunosuppressive agents and their use in therapy | |
| EP2830719A4 (en) | Method for movement in a physically configurable space and device for use with the method | |
| EP2968345A4 (en) | Dual mek/pi3k inhibitors and therapeutic methods using the same | |
| SG11201504638RA (en) | Cancer cell isolation device and cancer cell isolation method | |
| GB201305076D0 (en) | A portable storage and activity device | |
| EP2872973A4 (en) | Improvements in devices for use with computers | |
| HK1208735A1 (en) | Electrochromic cells and their use | |
| IL238453A0 (en) | Trans-clomiphene for use in cancer therapy | |
| GB201305940D0 (en) | Methods and arrays for use in the same | |
| EP3017440A4 (en) | Systems and methods for power management in a beacom | |
| EP2978521A4 (en) | Inclined baseplate in dehydrogenation reactor | |
| GB201308753D0 (en) | Compounds and their use in therapy | |
| GB201308217D0 (en) | Compounds and their use in therapy | |
| SG10201704704SA (en) | Cancer cell isolation device and cancer cell isolation method |